Effects of levothyroxine on growth hormone (gh) sensitivity in children with idiopathic short stature

García, Roberto J.; Íñiguez, Germán; Gaete, Ximena; Linares, Jeannette; Ocaranza, Paula; Ávila, Alejandra; Román, Rossana; Cassorla, Fernando

doi:10.1016/j.ghir.2014.04.004

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, GH influences the monodeiodination of FT4 to FT3; this reaction is also mediated by IGF-I [ 7 ]. In many children with GH deficiency, shortly after the start of GH replacement therapy, FT4 levels significantly decreased [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Strong Positive Correlation between TSH and Ghrelin in Euthyroid Non-Growth Hormone-Deficient Children with Short Stature

et al. 2020

View full text Add to dashboard Cite

The growth processes in children depend on the proper functioning of some hormones and growth factors. Recently, a positive correlation between ghrelin and TSH (thyroid stimulating hormone) in patients with hyper- and hypothyroidism was proved. Moreover, in hypothyroid rats with high ghrelin concentration, growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion was suppressed. We analyzed these relationships in euthyroid prepubertal children with idiopathic short stature (ISS). The analysis comprised concentration of ghrelin, GH in stimulating tests and during the night, as well as IGF-I, TSH, free thyroxine (FT4) and free triiodothyronine (FT3) in 85 children with ISS (36 girls, 49 boys) aged 9.65 ± 3.02 years (mean ± SD). A strong positive correlation between ghrelin and TSH was confirmed (r = +0.44, p < 0.05). A higher ghrelin but lower nocturnal GH and lower IGF-I were observed in children with higher normal TSH concentration than those in children with lower normal TSH. Interestingly, alterations of TSH level were without any impact on FT4 and FT3 concentrations. Summing up, in ISS prepubertal euthyroid children, ghrelin and TSH secretion are closely related. On the other hand, the higher the TSH, the lower the nocturnal GH and IGF-I levels. The contribution of the above findings in deterioration of growth processes requires further studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Strong Positive Correlation between TSH and Ghrelin in Euthyroid Non-Growth Hormone-Deficient Children with Short Stature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Childhood growth delay is a well-known condition and may manifest with other symptoms resulting from hypothyroidism. Many children with hypothyroidism have a relatively normal development after diagnosis and treatment of hypothyroidism [12][13][14].…”

Section: Discussionmentioning

confidence: 99%

The impact of juvenile hypothyroidism on stature

Al-Omari,

Omer

2023

JMedLife

View full text Add to dashboard Cite

Short stature with different alterations in the skeletal appearance usually results from juvenile hypothyroidism. The present case-control study was conducted to assess the effect of thyroid hormone deficiency on the height of young people and the prevalence of short stature in juvenile hypothyroidism. The research was conducted at the Al-Waffa Diabetic Centre between May and September 2022. The study group included 90 children with short stature, while the control group included 58 children. The statistical analysis was conducted using Minitab version 20. The results revealed that a low serum level of triiodothyronine (T3) was present in 2.2% of participants, while a low serum level of thyroxin (T4) was present in 36.7%. All subjects had elevated serum thyroid stimulating hormone (TSH). Female children had increased rates of short stature. Juvenile hypothyroidism results in various skeletal manifestations, including reduced height. Low serum thyroxin coupled with high serum thyroid stimulating hormone are common findings in juvenile hypothyroidism.

show abstract

Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children during therapy with recombinant human growth hormone

et al. 2018

View full text Add to dashboard Cite

This study aimed to evaluate the effects of thyroid hormone supplementation on growth rate of children with idiopathic short stature (ISS) and low-normal serum free thyroxine FT4 who were receiving growth hormone therapy. We selected 64 prepubertal children with FT4 levels in the lowest third of the normal range as the lower FT4 group, and these children were divided randomly into two subgroups: L-thyroxine (L-T4)-treated subgroup was treated with L-T4 (0.5-3.0 g/(kg·d)) from the beginning of the study, and the non-L-T4-treated subgroup received placebo. We also selected 39 ISS children with FT4 in the upper two-thirds of the normal range as the higher FT4 group. During the first year, the lower FT4 group featured lower FT3, FT4, thyroid stimulating hormone (TSH), and insulin-like growth factor-I standard deviation score (IGF-I SDS) and significantly lower height velocity (HV) compared with the higher FT4 group. However, in the lower FT4 group, the L-T4-treated subgroup presented higher FT4, FT3, TSH, and IGF-I SDS concentrations and significantly higher HV compared with children in the non-L-T4-treated subgroup. In children with ISS, the negative effect of thyroid hormone deficiency on growth rate should be considered when FT4 level lies in the low-normal range prior to recombinant human growth hormone treatment.

show abstract

Effects of levothyroxine on growth hormone (gh) sensitivity in children with idiopathic short stature

Cited by 4 publications

References 17 publications

Strong Positive Correlation between TSH and Ghrelin in Euthyroid Non-Growth Hormone-Deficient Children with Short Stature

Strong Positive Correlation between TSH and Ghrelin in Euthyroid Non-Growth Hormone-Deficient Children with Short Stature

The impact of juvenile hypothyroidism on stature

Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children during therapy with recombinant human growth hormone

Contact Info

Product

Resources

About